Literature DB >> 29162933

Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2.

Richard Jlf Lemmers1, Patrick J van der Vliet2, Judit Balog2, Jelle J Goeman3, Wibowo Arindrarto4, Yvonne D Krom5, Kirsten R Straasheijm2, Rashmie D Debipersad2, Gizem Özel2, Janet Sowden6, Lauren Snider7, Karlien Mul8, Sabrina Sacconi9, Baziel van Engelen8, Stephen J Tapscott7, Rabi Tawil6, Silvère M van der Maarel10.   

Abstract

Facioscapulohumeral muscular dystrophy is caused by incomplete repression of the transcription factor DUX4 in skeletal muscle as a consequence of D4Z4 macrosatellite repeat contraction in chromosome 4q35 (FSHD1) or variants in genes encoding D4Z4 chromatin repressors (FSHD2). A clinical hallmark of FSHD is variability in onset and progression suggesting the presence of disease modifiers. A well-known cis modifier is the polymorphic DUX4 polyadenylation signal (PAS) that defines FSHD permissive alleles: D4Z4 chromatin relaxation on non-permissive alleles which lack the DUX4-PAS cannot cause disease in the absence of stable DUX4 mRNA. We have explored the nature and relevance of a common variant of the major FSHD haplotype 4A161, which is defined by 1.6 kb size difference of the most distal D4Z4 repeat unit. While the short variant (4A161S) has been extensively studied, we demonstrate that the long variant (4A161L) is relatively common in the European population, is capable of expressing DUX4, but that DUX4 mRNA processing differs from 4A161S. While we do not find evidence for a difference in disease severity between FSHD carriers of an 4A161S or 4A161L allele, our study does uncover biallelic DUX4 expression in FSHD2 patients. Compared to control individuals, we observed an increased frequency of FSHD2 patients homozygous for disease permissive alleles, and who are thus capable of biallelic DUX4 expression, while SMCHD1 variant carriers with only one permissive allele were significantly more often asymptomatic. This suggests that biallelic DUX4 expression lowers the threshold for disease presentation and is a modifier for disease severity in FSHD2.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29162933      PMCID: PMC5838976          DOI: 10.1038/s41431-017-0015-0

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  12 in total

1.  Cis D4Z4 repeat duplications associated with facioscapulohumeral muscular dystrophy type 2.

Authors:  Richard J L F Lemmers; Patrick J van der Vliet; Jeroen P Vreijling; Don Henderson; Nienke van der Stoep; Nicol Voermans; Baziel van Engelen; Frank Baas; Sabrina Sacconi; Rabi Tawil; Silvère M van der Maarel
Journal:  Hum Mol Genet       Date:  2018-10-15       Impact factor: 6.150

2.  FSHD1 and FSHD2 form a disease continuum.

Authors:  Sabrina Sacconi; Audrey Briand-Suleau; Marilyn Gros; Christian Baudoin; Richard J L F Lemmers; Sophie Rondeau; Nadira Lagha; Pilvi Nigumann; Chiara Cambieri; Angela Puma; Françoise Chapon; Tanya Stojkovic; Christophe Vial; Françoise Bouhour; Michelangelo Cao; Elena Pegoraro; Philippe Petiot; Anthony Behin; Bras Marc; Bruno Eymard; Andoni Echaniz-Laguna; Pascal Laforet; Leonardo Salviati; Marc Jeanpierre; Gaël Cristofari; Silvère M van der Maarel
Journal:  Neurology       Date:  2019-04-12       Impact factor: 9.910

3.  High-resolution breakpoint junction mapping of proximally extended D4Z4 deletions in FSHD1 reveals evidence for a founder effect.

Authors:  Richard J L F Lemmers; Patrick J van der Vliet; David San Leon Granado; Nienke van der Stoep; Henk Buermans; Robin van Schendel; Joost Schimmel; Marianne de Visser; Rudy van Coster; Marc Jeanpierre; Pascal Laforet; Meena Upadhyaya; Baziel van Engelen; Sabrina Sacconi; Rabi Tawil; Nicol C Voermans; Mark Rogers; Silvère M van der Maarel
Journal:  Hum Mol Genet       Date:  2022-03-03       Impact factor: 5.121

4.  Chromosome 10q-linked FSHD identifies DUX4 as principal disease gene.

Authors:  Richard J L F Lemmers; Patrick J van der Vliet; Ana Blatnik; Judit Balog; Janez Zidar; Don Henderson; Rianne Goselink; Stephen J Tapscott; Nicol C Voermans; Rabi Tawil; George W A M Padberg; Baziel Gm van Engelen; Silvère M van der Maarel
Journal:  J Med Genet       Date:  2021-01-12       Impact factor: 6.318

5.  NuRD and CAF-1-mediated silencing of the D4Z4 array is modulated by DUX4-induced MBD3L proteins.

Authors:  Amy E Campbell; Sean C Shadle; Sujatha Jagannathan; Jong-Won Lim; Rebecca Resnick; Rabi Tawil; Silvère M van der Maarel; Stephen J Tapscott
Journal:  Elife       Date:  2018-03-13       Impact factor: 8.140

Review 6.  Long-Read Sequencing Emerging in Medical Genetics.

Authors:  Tuomo Mantere; Simone Kersten; Alexander Hoischen
Journal:  Front Genet       Date:  2019-05-07       Impact factor: 4.599

7.  Scapular dyskinesis in myotonic dystrophy type 1: clinical characteristics and genetic investigations.

Authors:  N C Voermans; R C van der Bilt; J IJspeert; J Y Hogrel; M Jeanpierre; A Behin; P Laforet; T Stojkovic; B G van Engelen; G W Padberg; S Sacconi; R J L F Lemmers; S M van der Maarel; B Eymard; G Bassez
Journal:  J Neurol       Date:  2019-08-31       Impact factor: 4.849

Review 8.  Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.

Authors:  Anna Greco; Remko Goossens; Baziel van Engelen; Silvère M van der Maarel
Journal:  Clin Genet       Date:  2020-03-04       Impact factor: 4.438

9.  Single-molecule optical mapping enables quantitative measurement of D4Z4 repeats in facioscapulohumeral muscular dystrophy (FSHD).

Authors:  Yi Dai; Pidong Li; Zhiqiang Wang; Fan Liang; Fan Yang; Li Fang; Yu Huang; Shangzhi Huang; Jiapeng Zhou; Depeng Wang; Liying Cui; Kai Wang
Journal:  J Med Genet       Date:  2019-09-10       Impact factor: 6.318

Review 10.  DUX4 Expression in FSHD Muscles: Focus on Its mRNA Regulation.

Authors:  Eva Sidlauskaite; Laura Le Gall; Virginie Mariot; Julie Dumonceaux
Journal:  J Pers Med       Date:  2020-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.